Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SVT-1C4610
- Development stage
- Unknown
- Lead developer
- Servatus Biopharmaceuticals
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
SVT-1C4610 is an investigational live microbial biotherapeutic (live biotherapeutic product) developed by Servatus Ltd for the treatment of Helicobacter pylori (H. pylori) infection. It is designed to function as a microbiome modulator, utilizing bacterial replacement and gastrointestinal microbiome modulation to address H. pylori colonization. Unlike traditional antibiotic-based triple or quadruple therapies, SVT-1C4610 aims to restore microbial balance in the gut. The drug is currently being evaluated in a two-stage Phase I clinical trial to assess its safety, tolerability, and preliminary efficacy as a monotherapy in healthy adults.
Beyond the preview
Go deeper on SVT-1C4610.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SVT-1C4610.